Novozymes A/S (NVZMY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Novozymes A/S (NVZMY) Materials & Commodity Exposure

Novozymes A/S is a global biotechnology leader specializing in industrial enzymes and microorganisms, serving diverse sectors including food, agriculture, and household care, with a strong commitment to sustainability and innovation.

What Is the Investment Thesis for NVZMY?

With a market capitalization of $30.6B, the company boasts a profit margin of 14.2% and a gross margin of 55.9%, indicating efficient operations. The ongoing trend towards sustainable solutions in various industries, particularly in agriculture and bioenergy, positions Novozymes favorably for growth. The company's focus on innovation and development of new enzyme solutions is expected to drive revenue growth, particularly as the global demand for sustainable and efficient production processes increases. However, investors should remain cautious of potential risks, including fluctuations in raw material costs and competitive pressures from emerging biotechnology firms.

Based on FMP financials and quantitative analysis

NVZMY Key Highlights

Market capitalization of $30.6B, reflecting a strong market presence.

• Profit margin of 14.2%, indicating effective cost management.
• Gross margin of 55.9%, exceeding industry averages.
• Return on equity (ROE) of 5.4%, showcasing shareholder value generation.
• Debt-to-equity ratio (D/E) of 29.42, indicating a conservative capital structure.

Who Are NVZMY's Competitors?

NVZMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NVZMY's Key Strengths?

Established leader in the industrial enzymes market.

• Strong commitment to sustainability and innovation.
• Diverse product offerings across multiple sectors.
• Robust global distribution network.

What Are NVZMY's Weaknesses?

Limited presence in emerging markets compared to competitors.

• Dependency on specific raw materials which may face price volatility.
• No dividend yield, which may deter income-focused investors.

What Could Drive NVZMY Stock Higher?

Launch of new enzyme products targeting sustainable agriculture in Q3 2026.

• Expansion into emerging markets with a focus on bioenergy solutions.
• Continued investment in R&D to enhance product offerings and efficiency.

What Are the Key Risks for NVZMY?

Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.

• Rich valuation — a P/E of 41.02 runs well above the Basic Materials sector’s ~21.40x, leaving little room for a miss.
• Fluctuating raw material costs impacting profit margins.
• Competitive pressures from emerging biotechnology firms.
• Regulatory changes affecting operational capabilities in key markets.

What Are the Growth Opportunities for NVZMY?

• Sustainable Agriculture: The global market for sustainable agricultural solutions is projected to reach $30 billion by 2027. Novozymes' innovative products in crop cultivation and bioyield enhancement position the company to capture significant market share as farmers increasingly adopt sustainable practices.
• Bioenergy Expansion: The bioenergy market is expected to grow at a CAGR of 8% through 2030, driven by the need for renewable energy sources. Novozymes' enzyme solutions for biomass transformation and fermentation processes are critical for biofuel production, presenting a substantial growth opportunity.
• Novozymes' extensive portfolio in food processing aids, particularly in baking and dairy, positions the company to capitalize on this growing demand for efficiency and quality in food production.
• Novozymes' specialized formulations for laundry and dishwashing provide a competitive edge in this expanding market.
• Novozymes' offerings in specialized lipases and proteases for biocatalysis are well-positioned to benefit from the increasing demand for biopharmaceutical solutions.

What Are NVZMY's Competitive Advantages?

• Strong brand reputation as a leader in the industrial enzymes market.
• Extensive research and development capabilities driving innovation.
• Diverse product portfolio catering to multiple industries.
• Established global presence with a broad customer base.

What Does NVZMY Do?

Founded in 1925, Novozymes A/S is a global biotechnology firm headquartered in Bagsvaerd, Denmark, renowned for its expertise in developing and distributing industrial enzymes, microorganisms, and probiotics. With a workforce of approximately 10,582 employees, Novozymes operates across multiple regions, including Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company’s extensive product range addresses various industries, such as Food and Beverages, where it supplies essential ingredients and processing aids for baking and dairy production. In Household Care, Novozymes delivers specialized formulations for laundry and dishwashing. The Agriculture sector benefits from its innovations in crop cultivation and animal health, while its Bioenergy and Industrial Processing division provides critical components for grain processing. Additionally, Novozymes enhances Textile, Pulp and Paper, and Leather Production processes through advanced enzymatic solutions. The company is also involved in Water and Waste Management, offering bioaugmentation strategies, and Pharmaceuticals, supplying vital enzymes for biocatalysis. Novozymes' commitment to sustainability and innovation has solidified its position as a leader in the industrial enzymes market, making it a key player in the global biotechnology landscape.

What Products and Services Does NVZMY Offer?

• Develop and distribute industrial enzymes for various applications.
• Provide microorganisms and probiotics for agricultural and health sectors.
• Offer specialized formulations for household cleaning products.
• Create solutions for bioenergy and industrial processing.
• Enhance food and beverage production with innovative processing aids.
• Deliver enzyme solutions for textile, pulp, and paper industries.

How Does NVZMY Make Money?

• Generate revenue through the sale of industrial enzymes and microorganisms.
• Provide customized solutions for various industry needs.
• Engage in research and development to innovate new products.
• Collaborate with partners to expand market reach and product applications.

What Industry Does NVZMY Operate In?

The specialty chemicals industry, particularly in biotechnology, is experiencing significant growth driven by increasing demand for sustainable solutions across various sectors. The global market for industrial enzymes is projected to expand as industries seek to enhance efficiency and reduce environmental impact. Novozymes A/S, as a leader in this space, benefits from its established reputation and innovative product offerings. The competitive landscape includes notable players such as ArcelorMittal S.A. (AMSYF), PT. Chandra Asri Petrochemical Tbk (PTPIF), Givaudan S.A. (GVDNY), Akzo Nobel N.V. (AKZOY), and Sika AG (SXYAY), each vying for market share in a rapidly evolving industry.

Who Are NVZMY's Key Customers?

• Food and beverage manufacturers seeking processing aids.
• Agricultural companies focused on sustainable crop solutions.
• Household care brands looking for effective cleaning formulations.
• Bioenergy producers requiring enzyme solutions for production.
• Textile and paper industries aiming to enhance processing efficiency.

Company Profile

Novozymes A/S operates in the Specialty Chemicals industry within the Basic Materials sector. It is headquartered in Lyngby, Denmark.

Novozymes A/S Financial Trajectory

Novozymes A/S (NVZMY) reported $1.12B in revenue for Q2 FY2026, a decline of 1.9% compared to the prior quarter. The company recorded net income of $171.6M, with diluted EPS of $0.37. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Basic Materials. Across the four most recent quarters, NVZMY averaged $-0.13 in diluted EPS.

How Novozymes A/S Is Valued

Novozymes A/S carries a market capitalization of $30.6B, placing it in the large-cap category. Relative to its peer group, NVZMY's quantitative score of 62/100 is roughly in line with the peer average of 53/100.

Return on equity for Novozymes A/S stands at 5.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.6%, showing how much profit it generates from its asset base. NVZMY trades at a trailing price-to-earnings ratio of 41.02, above the Basic Materials sector average of ~21.40x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.3%, the inverse of the P/E and a quick read on earnings relative to price.

Novozymes A/S's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 23.56 places it in the safe zone, indicating low near-term bankruptcy risk.

Novozymes A/S has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 20.7% below estimates on average.

NVZMY Financials

NVZMY Latest News

NVZMY Analyst Consensus

NVZMY MoonshotScore

Common Questions About NVZMY (Basic Materials)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources